IV fluid transfer device market seen reaching $10.55B by 2030

The global market for intravenous fluid transfer drug devices is projected to rise from $7.85 billion in 2025 to $10.55 billion by 2030, according to The Business Research Company. Growth is tied to higher hospital admissions, smarter infusion technology and broader use in oncology, neurology and home care.

Why it matters: - Intravenous fluid transfer drug devices are central to delivering fluids and medications quickly, accurately and under sterile conditions. - Rising demand for these devices tracks with more hospital procedures, more chronic disease care and wider use of infusion therapy outside hospitals. - The market’s growth points to continued investment in safer, more precise drug-delivery systems.

What happened: - The Business Research Company released its Intravenous Fluid Transfer Drug Devices Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the market will grow from $7.85 billion in 2025 to $8.35 billion in 2026, a 6.3% compound annual growth rate. - The market is projected to reach $10.55 billion by 2030, with a 6.0% CAGR over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - The report links recent market growth to continued use of traditional IV sets, more hospital and clinical procedures, limited availability of advanced smart infusion devices, growing awareness of IV therapy benefits and broader adoption of PVC infusion bags. - Expected growth drivers include smart infusion pump innovation, rising demand for pre-filled and multi-chamber infusion bags, and expanded use in oncology and neurology. - Home healthcare and ambulatory infusion services are also expected to add demand. - Stricter regulatory and quality controls are another growth factor. - The report identifies greater adoption of smart infusion devices, more use of needleless connectors and safety IV sets, and broader IV therapy use in chronic and critical care as key trends. - The market is also shifting toward sterility, dosage accuracy and flow regulation. - Intravenous fluid transfer drug devices deliver fluids and medications directly into the bloodstream through an intravenous line. - These devices are designed to support hydration, medication delivery and intensive care while helping prevent contamination and infection. - Rising hospital admissions remain a major demand driver. - The report cites aging populations, chronic disease prevalence, better diagnostic technology, improved healthcare access, lifestyle-related conditions and ongoing medical innovation as contributors to higher admissions. - In March 2023, GOV.UK reported COVID-19 hospital admissions in England at 10.62 per 100,000 people, while ICU and high-dependency unit admissions stood at 0.28 per 100,000. - Most regions saw minor increases, and rates were stable across age groups.

Between the lines: - The market is moving toward devices that combine convenience with tighter control, which favors smart pumps and safety-focused accessories. - Growing use beyond hospitals suggests manufacturers are building for more distributed care settings, not just inpatient treatment. - Regulatory pressure appears to be pushing product upgrades rather than slowing adoption.

What’s next: - The report expects continued expansion in smart infusion systems and advanced infusion consumables through 2030. - Demand is likely to build in oncology, neurology, home healthcare and ambulatory infusion. - Manufacturers will likely keep focusing on accuracy, sterility and regulatory compliance as competitive differentiators.

The bottom line: - The intravenous fluid transfer drug devices market is on a steady growth path, with smarter, safer infusion technology driving the next phase of expansion.